BridgeBio Cuts Interest Costs with Strategic $550 Million Note Offering

Palo Alto, Friday, 16 January 2026.
BridgeBio Pharma is capitalizing on market strength to optimize its balance sheet, pricing $550 million in new notes at a remarkably low 0.75% interest rate. This strategic refinancing extends debt maturity to 2033 and includes a confident 45% conversion premium, significantly lowering borrowing costs compared to the existing 2027 notes.